Profile data is unavailable for this security.
About the company
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
- Revenue in INR (TTM)28.93bn
- Net income in INR-3.43bn
- Incorporated1999
- Employees2.39k
- LocationWockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
- Phone+91 2 226534444
- Fax+91 2 226523905
- Websitehttp://www.wockhardt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 86.14bn | 1.41k | 42.88 | 16.00 | 37.72 | 7.48 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 90.40bn | 447.00 | 57.42 | -- | 49.42 | 13.01 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
F D C Ltd | 20.45bn | 3.14bn | 91.82bn | 6.66k | 29.35 | -- | 25.82 | 4.49 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
Strides Pharma Science Ltd | 42.09bn | -475.19m | 118.30bn | 3.07k | -- | -- | 85.63 | 2.81 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Granules India Ltd | 47.01bn | 4.92bn | 130.85bn | 4.12k | 26.61 | -- | 18.61 | 2.78 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 134.06bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 141.13bn | 2.01k | 31.64 | -- | 28.11 | 6.15 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
Marksans Pharma Ltd | 22.68bn | 3.34bn | 144.26bn | 2.00k | 43.18 | -- | 34.80 | 6.36 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 147.43bn | 859.00 | 30.95 | -- | 27.30 | 8.39 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
Wockhardt Ltd | 28.93bn | -3.43bn | 158.40bn | 2.39k | -- | -- | -- | 5.48 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.85bn | 1.65k | 48.76 | -- | 41.12 | 10.02 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Sanofi India Ltd | 23.83bn | 4.30bn | 166.05bn | 2.17k | 38.64 | 24.26 | 35.48 | 6.97 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 171.82bn | 940.00 | 179.24 | -- | 154.92 | 12.38 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Eris Lifesciences Ltd | 22.62bn | 3.80bn | 185.98bn | 3.08k | 48.96 | -- | 30.47 | 8.22 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 190.99bn | 995.00 | 34.59 | -- | 20.51 | 2.79 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 219.16bn | 14.86k | 34.80 | -- | 24.21 | 3.48 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Jul 2024 | 2.91m | 1.90% |
ICICI Prudential Asset Management Co. Ltd.as of 31 Aug 2024 | 1.95m | 1.27% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 1.09m | 0.71% |
Samco Asset Management Pvt. Ltd.as of 31 Aug 2024 | 752.73k | 0.49% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 730.99k | 0.48% |
Invesco Asset Management (India) Pvt Ltd.as of 31 Aug 2024 | 486.36k | 0.32% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Aug 2024 | 483.56k | 0.32% |
Norges Bank Investment Managementas of 31 Dec 2023 | 351.08k | 0.23% |
SSgA Funds Management, Inc.as of 05 Sep 2024 | 292.06k | 0.19% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Aug 2024 | 232.11k | 0.15% |